AG-1024 Sensitizes Sorafenib-Resistant Hepatocellular Carcinoma Cells to Sorafenib via Enhancing G1/S Arrest.

Wei ZhouWeiyang LouJunru ChenBisha DingBinjie ChenHaiyang XieLin ZhouShushen ZhenDonghai Jiang

Published in: OncoTargets and therapy (2021)

The current findings indicate that sub-toxic AG-1024 may be a promising therapeutic agent in enhancing the sensitivity in HCC cells to sorafenib, bringing hope to HCC patients refractory to sorafenib treatment.

Keyphrases

induced apoptosis
end stage renal disease
chronic kidney disease
newly diagnosed
quantum dots
prognostic factors
peritoneal dialysis
highly efficient
cell cycle
patient reported outcomes
cell proliferation
replacement therapy
pi k akt